肿瘤细胞治疗研究
英文原题：Approved CAR-T therapies have reproducible efficacy and safety in clinical practice.
CAR-T细胞疗法已确立为血液系统恶性肿瘤的高效治疗方法。
CAR-T细胞疗法已成为治疗血液系统恶性肿瘤的高效方法。目前有六种商业化CAR-T产品已获FDA批准，用于B-ALL、LBCL、MCL、FL、MM和CLL/SLL等疾病。真实世界研究使我们能够评估普通人群的治疗结局，以确定其与原始试验入组患者相比的疗效和安全性。基于多项设计良好的、代表多样化人群的真实世界研究，我们报告称，导致这些疗法获批的原始试验的结局与临床实践中的结局相当。
CAR-T cell therapy has established itself as a highly effective treatment for hematological malignancies. There are currently six commercial CAR-T products that have been FDA approved for diseases such as B-ALL, LBCL, MCL, FL, MM, and CLL/SLL. "Real-world" studies allow us to evaluate outcomes from the general population to determine their efficacy and safety compared to those who were included in the original trials. Based on several well conducted "Real-world" studies that represent diverse populations, we report that outcomes from the original trials that led to the approval of these therapies are comparable to those in practice.
MEMBER ACCOUNT
登录成功会直接打开下一页。
